Healthy Subjects > PF-07209326 > Paid

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

Recruiting in Palo Alto (17 mi)

+15 other locations

Age: Any Age

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Pfizer

Trial Summary

What is the purpose of this trial?

This trial tests a new drug called PF-07209326 to see if it is safe and how it behaves in the body. It starts with healthy people and then moves to those with sickle cell disease. The study checks how the drug moves through and affects the body.

Eligibility Criteria

Inclusion Criteria

1. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).

Participant Groups

Group I: Treatment for SCD Experimental Treatment 1 Intervention

Participants will receive a multiple dose of subcutaneous PF-07209326

Group II: Treatment Healthy Participants Experimental Treatment 1 Intervention

Participants will receive single ascending doses of subcutaneous (SC) or intravenous PF-07209326

Group III: Placebo Healthy Participants Placebo Group 1 Intervention

Participants will receive matching placebo

Find A Clinic Near You

Research locations nearby Select from list below to view details:

Howard University Hospital Washington, United States

CUIMC Research Pharmacy New York, NY

Columbia University Medical Center - Herbert Irving Pavilion New York, NY

CUMC Research Pharmacy New York, NY

More Trial Locations

Who is running the clinical trial?

Pfizer Lead Sponsor

References